首頁 > 市場調查報告書 > 製藥

癌症呼吸器

市場調查報告書

商品編碼

1673027

非小細胞肺癌市場按類型、治療、最終用戶和地區分類

Non-Small Cell Lung Cancer Market, By Type, By Treatment, By End User, By Geography

出版日期: 2025年02月12日 | 出版商:

Coherent Market Insights | 英文 175 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球非小細胞肺癌市場規模估計為 286.1 億美元，預計到 2032 年將達到 543.8 億美元，2025 年至 2032 年的複合年成長率為 9.6%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	286.1億美元
效能資料	2020-2024	預測期	2025-2032
預測期：2025 年至 2032 年複合年成長率	9.60％	2032 年金額預測	543.8億美元

數字。 2025 年非小細胞肺癌各地區市場佔有率（%）

非小細胞肺癌（NSCLC）是最常見的肺癌類型，約佔所有肺癌的85%。它是全球癌症死亡的主要原因之一。全球非小細胞肺癌市場的成長受到吸煙習慣和環境污染日益普遍、先進治療方法研發活動活性化以及對標靶治療和個性化治療的需求不斷增加等因素的推動。然而，高昂的治療成本阻礙了市場的成長。

市場動態

全球非小細胞肺癌市場的成長受到已開發國家和新興國家吸菸率上升、環境污染程度加劇以及人口老化的推動。根據世界衛生組織統計，全球每年報告約180萬新發肺癌病例，其中大多數為非小細胞肺癌。標靶治療和癌症治療方法的進步為市場相關人員提供了機會。然而，標靶治療的高成本以及低收入國家缺乏認知阻礙了市場的成長。此外，藥物在測試中失敗的風險也會對研發活動產生負面影響。

研究的主要特點

本報告對全球非小細胞肺癌市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數，介紹了全球非小細胞肺癌市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球非小細胞肺癌市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過全球非小細胞肺癌市場分析中使用的各種策略矩陣來促進他們的決策。

公司簡介
- F. Hoffmann-La Roche Ltd
- Honeywell International Inc.
- AstraZeneca PLC
- Merck &Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG

第 10 章分析師建議

興衰
一致的機會地圖

第 11 章章節

參考
調查方法

簡介目錄

Product Code: CMI241

Global Non-Small Cell Lung Cancer Market is estimated to be valued at USD 28.61 Bn in 2025 and is expected to reach USD 54.38 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 28.61 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	9.60%	2032 Value Projection:	USD 54.38 Bn

Figure. Non-Small Cell Lung Cancer Market Share (%), By Region 2025

Non-Small Cell Lung Cancer Market - IMG1

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.

Market Dynamics:

Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.

Key features of the study:

This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.

Detailed Segmentation-

By Type
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neuroendocrine Tumors
Treatment
- Chemotherapy
- Targeted Therapy
- Bevacizumab
- Necitumumab
- Ramucirumab
- Immunotherapy
- Nivolumab
- Atezolizumab
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Hoffmann-La Roche Ltd
- Honeywell International Inc.
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Non-Small Cell Lung Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Non-Small Cell Lung Cancer Market, By Type, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Adenocarcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Squamous Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Large Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Large Cell Neuroendocrine Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Non-Small Cell Lung Cancer Market, By Treatment, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bevacizumab (Avastin)
Necitumumab (Portrazza)
Ramucirumab (Cyramza)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Nivolumab (Opdivo)
Atezolizumab (Tecentriq)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Non-Small Cell Lung Cancer Market, By End User, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Hospitals
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Home Care
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Non-Small Cell Lung Cancer Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Honeywell International Inc.
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca PLC
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG